适合移植的套细胞淋巴瘤患者接受苯达莫司汀或含利妥昔单抗的高剂量阿糖胞苷诱导治疗
研究回顾性比较了适合移植的套细胞淋巴瘤(MCL)患者接受一线利妥昔单抗联合苯达莫司汀(R-B)与R-CHOP/R-DHAP方案的结局。R-B组97例,R-CHOP/R-DHAP组232例。两组无进展生存期(PFS)在未调整(HR 0.87;95%CI 0.53-1.41;P=0.56)和调整后(HR 0.79;95%CI 0.45-1.37;P=0.40)比较均无差异。作者认为R-B联合自体干细胞移植和利妥昔单抗维持是可行有效的一线治疗,结局与R-CHOP/R-DHAP联合ASCT相当。
要点
- R-B组总缓解率90%(完全缓解54%),77%接受自体干细胞移植,78%接受利妥昔单抗维持。
- R-CHOP/R-DHAP组总缓解率94%(完全缓解54%),78%接受自体干细胞移植,2%接受利妥昔单抗维持。
- 两组PFS在未调整和调整后比较均无显著差异。
核心结论
- 在适合移植的年轻MCL患者中,R-B联合ASCT和利妥昔单抗维持是可行有效的一线治疗,结局与R-CHOP/R-DHAP联合ASCT相当。
研究设计与样本
- 研究为回顾性调整比较,在BC Cancer连续识别97例18至65岁、II-IV期MCL并接受R-B治疗的患者,与MCL Younger试验中随机分配至R-CHOP/R-DHAP arm的232例患者进行比较。
主要发现
- R-B组总缓解率为90%(完全缓解54%);R-CHOP/R-DHAP组总缓解率为94%(完全缓解54%)。
- R-B组77%的患者接受ASCT,78%接受利妥昔单抗维持;R-CHOP/R-DHAP组78%接受ASCT,2%接受利妥昔单抗维持。
- PFS未调整比较:HR 0.87(95%CI 0.53-1.41;P=0.56);调整后比较:HR 0.79(95%CI 0.45-1.37;P=0.40)。
- 次要终点在未调整或调整分析中均无明确差异。
关键数值与推荐
- 主要终点为两组间PFS比较的风险比(HR),调整因素包括MCL国际预后指数(MIPI)、Ki67指数和母细胞样/多形性形态。
- 两组在Ann Arbor分期、乳酸脱氢酶、MIPI、母细胞样形态和MCL35分型方面相似。
临床怎么用
- 作者认为R-B联合ASCT和利妥昔单抗维持是可行有效的一线治疗,结局与R-CHOP/R-DHAP联合ASCT相当。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to explore differences in outcomes between first-line rituximab plus bendamustine (R-B) and R-CHOP/R-DHAP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, cytarabine, cisplatin) in transplant-eligible patients with mantle cell lymphoma (MCL). A population-based cohort of 97 patients aged 18 to 65 years with stage II-IV MCL, consecutively treated with R-B was retrospectively identified at BC Cancer. Baseline characteristics, response rates, and outcomes were compared with the cohort of 232 patients with MCL randomized to the R-CHOP/R-DHAP arm of the MCL Younger trial. The primary endpoint was the hazard ratio (HR) of the progression-free survival (PFS) comparison between both groups, adjusted for MCL International Prognostic Index (MIPI), Ki67 index, and blastoid/ pleomorphic morphology. Ann Arbor stage, lactate dehydrogenase, MIPI, blastoid morphology, and MCL35 assignments were similar between both groups. The overall response rate (ORR) to R-B was 90% (54% complete response [CR]); 77% of patients proceeded to autologous stem cell transplantation (ASCT) and 78% received maintenance rituximab (MR). The ORR to R-CHOP/R-DHAP was 94% (54% CR); 78% proceeded to ASCT and 2% received MR. There were no differences in PFS in unadjusted (HR, 0.87; 95% confidence interval [CI], 0.53-1.41; P = .56) or adjusted (HR, 0.79; 95% CI, 0.45-1.37; P = .40) comparisons. There were no clear differences in secondary endpoints in unadjusted or adjusted analyses. This retrospective adjusted comparison of 2 independent cohorts of younger patients with MCL suggests that R-B with ASCT and maintenance rituximab is a feasible and effective first-line treatment, with outcomes comparable to R-CHOP/R-DHAP with ASCT.
引用
- Villa D, Hoster E, Hermine O, et al. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. Blood Adv. 2022. PMID: 35439293. doi:10.1182/bloodadvances.2022007371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。